GERRESHEIMER AG (GXI.DE) Stock Fundamental Analysis
FRA:GXI - Deutsche Boerse Ag - DE000A0LD6E6 - Common Stock - Currency: EUR
Overall GXI gets a fundamental rating of 4 out of 10. We evaluated GXI against 19 industry peers in the Life Sciences Tools & Services industry. While GXI is still in line with the averages on profitability rating, there are concerns on its financial health. GXI has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year GXI was profitable.
In the past year GXI had a positive cash flow from operations.
GXI had positive earnings in each of the past 5 years.
GXI had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
GXI has a Return On Assets (1.63%) which is in line with its industry peers.
With a decent Return On Equity value of 5.20%, GXI is doing good in the industry, outperforming 63.16% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 4.57%, GXI is in line with its industry, outperforming 47.37% of the companies in the same industry.
GXI had an Average Return On Invested Capital over the past 3 years of 6.14%. This is in line with the industry average of 7.38%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.63% | ||
| ROE | 5.2% | ||
| ROIC | 4.57% |
ROA(3y)3.04%
ROA(5y)3.09%
ROE(3y)7.67%
ROE(5y)8.3%
ROIC(3y)6.14%
ROIC(5y)6.08%
1.3 Margins
Looking at the Profit Margin, with a value of 3.77%, GXI is in line with its industry, outperforming 47.37% of the companies in the same industry.
GXI's Profit Margin has been stable in the last couple of years.
GXI has a worse Operating Margin (8.65%) than 68.42% of its industry peers.
GXI's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 28.95%, GXI is doing worse than 68.42% of the companies in the same industry.
GXI's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.65% | ||
| PM (TTM) | 3.77% | ||
| GM | 28.95% |
OM growth 3Y-0.21%
OM growth 5Y2.69%
PM growth 3Y-1.23%
PM growth 5Y-1.47%
GM growth 3Y0.37%
GM growth 5Y1.38%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so GXI is destroying value.
Compared to 1 year ago, GXI has about the same amount of shares outstanding.
GXI has more shares outstanding than it did 5 years ago.
GXI has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.89, we must say that GXI is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.89, GXI is not doing good in the industry: 78.95% of the companies in the same industry are doing better.
GXI has a Debt/Equity ratio of 0.60. This is a neutral value indicating GXI is somewhat dependend on debt financing.
GXI has a Debt to Equity ratio (0.60) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.89 |
ROIC/WACC0.58
WACC7.81%
2.3 Liquidity
A Current Ratio of 0.61 indicates that GXI may have some problems paying its short term obligations.
With a Current ratio value of 0.61, GXI is not doing good in the industry: 84.21% of the companies in the same industry are doing better.
GXI has a Quick Ratio of 0.61. This is a bad value and indicates that GXI is not financially healthy enough and could expect problems in meeting its short term obligations.
GXI has a worse Quick ratio (0.34) than 84.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.61 | ||
| Quick Ratio | 0.34 |
3. Growth
3.1 Past
The earnings per share for GXI have decreased by -0.88% in the last year.
The Earnings Per Share has been decreasing by -8.23% on average over the past years.
The Revenue has been growing slightly by 4.55% in the past year.
GXI shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.90% yearly.
EPS 1Y (TTM)-0.88%
EPS 3Y4.26%
EPS 5Y-8.23%
EPS Q2Q%-29.23%
Revenue 1Y (TTM)4.55%
Revenue growth 3Y10.77%
Revenue growth 5Y7.9%
Sales Q2Q%11.57%
3.2 Future
Based on estimates for the next years, GXI will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.54% on average per year.
The Revenue is expected to grow by 8.77% on average over the next years. This is quite good.
EPS Next Y12.58%
EPS Next 2Y14.26%
EPS Next 3Y15.62%
EPS Next 5Y10.54%
Revenue Next Year21.4%
Revenue Next 2Y14.56%
Revenue Next 3Y12.32%
Revenue Next 5Y8.77%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
GXI is valuated reasonably with a Price/Earnings ratio of 10.92.
Based on the Price/Earnings ratio, GXI is valued cheaper than 100.00% of the companies in the same industry.
GXI is valuated cheaply when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 8.02, the valuation of GXI can be described as reasonable.
100.00% of the companies in the same industry are more expensive than GXI, based on the Price/Forward Earnings ratio.
GXI's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 21.76.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.92 | ||
| Fwd PE | 8.02 |
4.2 Price Multiples
84.21% of the companies in the same industry are more expensive than GXI, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 9.25 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as GXI's earnings are expected to grow with 15.62% in the coming years.
PEG (NY)0.87
PEG (5Y)N/A
EPS Next 2Y14.26%
EPS Next 3Y15.62%
5. Dividend
5.1 Amount
GXI has a yearly dividend return of 0.08%, which is pretty low.
GXI's Dividend Yield is slightly below the industry average, which is at 0.71.
With a Dividend Yield of 0.08, GXI pays less dividend than the S&P500 average, which is at 2.35.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.08% |
5.2 History
The dividend of GXI has a limited annual growth rate of 0.94%.
Dividend Growth(5Y)0.94%
Div Incr Years0
Div Non Decr Years6
5.3 Sustainability
GXI pays out 56.16% of its income as dividend. This is a bit on the high side, but may be sustainable.
The dividend of GXI is growing, but earnings are growing more, so the dividend growth is sustainable.
DP56.16%
EPS Next 2Y14.26%
EPS Next 3Y15.62%
FRA:GXI (7/11/2025, 7:00:00 PM)
49.02
-1.48 (-2.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners87.13%
Inst Owner ChangeN/A
Ins Owners4.92%
Ins Owner ChangeN/A
Market Cap1.69B
Analysts73.33
Price Target75.08 (53.16%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.08% |
Yearly Dividend1.32
Dividend Growth(5Y)0.94%
DP56.16%
Div Incr Years0
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.31%
Min EPS beat(2)17.79%
Max EPS beat(2)18.84%
EPS beat(4)3
Avg EPS beat(4)10.77%
Min EPS beat(4)-2%
Max EPS beat(4)18.84%
EPS beat(8)5
Avg EPS beat(8)4.46%
EPS beat(12)8
Avg EPS beat(12)4.54%
EPS beat(16)9
Avg EPS beat(16)2.98%
Revenue beat(2)0
Avg Revenue beat(2)-1.15%
Min Revenue beat(2)-1.59%
Max Revenue beat(2)-0.72%
Revenue beat(4)0
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-1.59%
Max Revenue beat(4)-0.72%
Revenue beat(8)2
Avg Revenue beat(8)-0.89%
Revenue beat(12)5
Avg Revenue beat(12)-0.41%
Revenue beat(16)6
Avg Revenue beat(16)-0.13%
PT rev (1m)-21.58%
PT rev (3m)-26.29%
EPS NQ rev (1m)-10.75%
EPS NQ rev (3m)-24.21%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.28%
Revenue NQ rev (1m)-1.1%
Revenue NQ rev (3m)-1.98%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.92 | ||
| Fwd PE | 8.02 | ||
| P/S | 0.81 | ||
| P/FCF | N/A | ||
| P/OCF | 9.14 | ||
| P/B | 1.12 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.25 |
EPS(TTM)4.49
EY9.16%
EPS(NY)6.11
Fwd EY12.46%
FCF(TTM)-5.44
FCFYN/A
OCF(TTM)5.36
OCFY10.94%
SpS60.5
BVpS43.79
TBVpS-7.82
PEG (NY)0.87
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.63% | ||
| ROE | 5.2% | ||
| ROCE | 6.16% | ||
| ROIC | 4.57% | ||
| ROICexc | 4.87% | ||
| ROICexgc | 13.87% | ||
| OM | 8.65% | ||
| PM (TTM) | 3.77% | ||
| GM | 28.95% | ||
| FCFM | N/A |
ROA(3y)3.04%
ROA(5y)3.09%
ROE(3y)7.67%
ROE(5y)8.3%
ROIC(3y)6.14%
ROIC(5y)6.08%
ROICexc(3y)6.5%
ROICexc(5y)6.42%
ROICexgc(3y)14.47%
ROICexgc(5y)16.32%
ROCE(3y)8.29%
ROCE(5y)8.2%
ROICexcg growth 3Y-17.1%
ROICexcg growth 5Y-18.13%
ROICexc growth 3Y-1.3%
ROICexc growth 5Y1.06%
OM growth 3Y-0.21%
OM growth 5Y2.69%
PM growth 3Y-1.23%
PM growth 5Y-1.47%
GM growth 3Y0.37%
GM growth 5Y1.38%
F-Score3
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.29 | ||
| Cap/Depr | 170.95% | ||
| Cap/Sales | 17.86% | ||
| Interest Coverage | 2.93 | ||
| Cash Conversion | 46.44% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.61 | ||
| Quick Ratio | 0.34 | ||
| Altman-Z | 0.89 |
F-Score3
WACC7.81%
ROIC/WACC0.58
Cap/Depr(3y)167.14%
Cap/Depr(5y)152.09%
Cap/Sales(3y)15.92%
Cap/Sales(5y)14.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.88%
EPS 3Y4.26%
EPS 5Y-8.23%
EPS Q2Q%-29.23%
EPS Next Y12.58%
EPS Next 2Y14.26%
EPS Next 3Y15.62%
EPS Next 5Y10.54%
Revenue 1Y (TTM)4.55%
Revenue growth 3Y10.77%
Revenue growth 5Y7.9%
Sales Q2Q%11.57%
Revenue Next Year21.4%
Revenue Next 2Y14.56%
Revenue Next 3Y12.32%
Revenue Next 5Y8.77%
EBIT growth 1Y-15.63%
EBIT growth 3Y10.54%
EBIT growth 5Y10.8%
EBIT Next Year139.92%
EBIT Next 3Y43.59%
EBIT Next 5Y26.2%
FCF growth 1Y-179.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.34%
OCF growth 3Y4.26%
OCF growth 5Y4.49%